Obesity and Retinopathy in Diabetes

Snježana Kaštelan1*, Martina Tomic2, Antonela Gverović Antunica3 and Jasminka Salopek Rabatić1

1Department of Ophthalmology, Clinical Hospital Dubrava, Avenija Gjoka Šuška 6, 10000 Zagreb, Croatia
2Department of Ophthalmology, University Clinic Vuk Vrhovac, Clinical Hospital Merkur, Zajčeva 19, 10000 Zagreb, Croatia
3Department of Ophthalmology, General Hospital Dubrovnik, Dr. Roka Mitića 2, 20000 Dubrovnik, Croatia

*Corresponding author: Snježana Kaštelan, Department of Ophthalmology, Clinical Hospital Dubrava, Avenija Gjoka Šuška 6, 10000 Zagreb, Croatia, Tel: +385 1 290 3396; Fax: +385 1 290 3396; E-mail: snjezanka@kastelan@yahoo.com

Received date: December 13, 2013; Accepted date: February 17, 2014; Published date: February 20, 2014

Copyright: ©2014 Kaštelan S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Diabetes mellitus a chronic metabolic disorder is a fast-growing global problem with significant social, health and economic consequences. It is estimated to have affected 366 million people worldwide and is expected to nearly double by 2030 with this rising trend observed for both type 1 and type 2 diabetes. An ageing population and rising prevalence of obesity reaching almost epidemic proportions are the main reasons for this increase. Diabetic retinopathy (DR) a common and progressive microvascular complication of diabetes represents one of the leading causes of vision impairment and blindness in working-age adults in developed countries. Epidemiological and clinical studies have confirmed that the main risk factors for DR are diabetes duration, prolonged poor glycaemic control, hypertension and hyperlipidemia. In addition to the well-known risk factors increasing attention is assigned to obesity specifically due to its frequency and inter-relationship with diabetes. To date this relationship has been examined in a number of epidemiologic studies giving conflicting results with most studies confirming the positive association. Although the underlying pathophysiological mechanisms supporting the relationship between obesity and DR are yet to be defined several biological theories have been suggested comprising the potential involvement of platelet function, blood viscosity, aldose reductase activity, vaso proliferative parameters, oxidative stress and inflammation. Given that weight is changeable and can be modified by lifestyle intervention opens up implications for further research and intervention in order to elucidate the role of obesity and body weight variations on the pathogenesis of DR.

Key words: Obesity; Diabetic retinopathy; Risk factor, Pathogenesis

Diabetes Mellitus and Obesity

Overweight (body mass index, BMI ≥ 25 kg/m²) and obesity (BMI ≥ 30 kg/m²) have become a growing global public health problem with increasing prevalence in many affluent societies as well as in developing countries [1-3]. Currently 300 million people are considered to be obese and due to this rising trend it is anticipated that this figure could double by the year 2025. Addressing the problem of obesity becomes important since being a disease itself it represents a risk for many metabolic and cardiovascular diseases including diabetes [4]. Diabetes mellitus another widespread and serious public health issue represents the most frequent endocrine disease in developed countries. It is estimated to have affected 366 million people worldwide and is expected to nearly double by 2030 with this growing trend observed for both type 1 and type 2 diabetes [5-8]. The number of patients with type 2 diabetes is rapidly increasing and it is projected that by 2025 there will be 380 million people affected and 418 million people with impaired glucose tolerance owing to an increase in obesity, inactivity, life span extension and better detection of the disease [9]. Type 1 is less widespread, accounting for 5–10% of the total cases of diabetes and its increased incidence is also seen across the world in various population studies with the range being between 2% and 5% [5-8]. Contemporary studies suggest that possible causes of this epidemic include the role of infections, early childhood diet, environmental pollutants, insulin resistance and recently more significance has been given to obesity [8]. As already stated obesity is a chronic disease with a rising prevalence across all age groups over the last 20 years [10] and like diabetes it is also a dysmetabolic disorder whose long term complications include severe impairment of the vascular system [10-12]. The relationship between obesity and type 2 diabetes is well known with growing evidence also confirming its connection with type 1 diabetes. Libman et al. reported that 50% of young Americans with type 1 diabetes are overweight or obese and some studies have suggested that weight gain may also be an accelerating factor for the onset of this type of diabetes and may contribute to its rising incidence as confirmed in type 2 [10].

Diabetic Retinopathy: Epidemiology and Risk Factors

Diabetes mellitus represents one of the most detrimental diseases and significant public health problems due its growing incidence and prevalence as well as high risk of macro- and microvascular complications among which diabetic retinopathy (DR) takes an important place [9,13]. Despite the availability of effective treatment DR remains a leading cause of acquired blindness in working-age adults and has been estimated to represent 12% of blindness in developed countries [14,15]. Although type 1 diabetes is much less common its relevance should not be disregarded since the incidence of any stage of retinopathy in patients with type 1 diabetes is higher than in those with type 2 and the advanced forms of DR usually develop throughout the patients most productive age [5-9]. According to a study conducted to estimate the global prevalence of DR 35% of people with diabetes had some form of DR, 7% had proliferative DR (PDR), 7% had DME (diabetic macular oedema) whilst 10% had vision
threatening DR, defined as the presence of PDR and/or DME [16]. Prevalence of DR in individuals with long-standing diabetes (20 years or more) exceeded 50% [17]. Furthermore age standardized prevalence of any form of DR in type 1 diabetic subjects aged 20-79 years after 10 to 20 years of diabetes duration was 55.55% and 86.22% after more than 20 years whilst prevalence of PDR after 10 to 20 years was 19.46% and 40.36% after more than 20 years [16]. The diagnosis of type 2 diabetes is often preceded by years of undiagnosed hyperglycaemia. Thus in a number of patients DR is in fact present at the time of diagnosis: 37% of them already having microaneurisms or more severe retinopathy in one and 18% having retinopathy in both eyes [18,19].

The prevalence of retinopathy increases with the duration of diabetes and is related to hyperglycemia, hypertension, hyperlipidemia, pregnancy, genetic predisposition, nephropathy and anemia as confirmed by many previous epidemiological and clinical studies [20-24]. Tight glycaemic control, strict hypertension and hyperlipidemia treatment cannot entirely eliminate the risk of microvascular diabetic complication and therefore there is a continuing need for the development of new management strategies [14,15,25-27]. In addition to the well-known risk factors recently increasing attention is assigned to obesity specifically due to its continuing need for the development of new management strategies [14,15,25-27]. In addition to the well-known risk factors recently increasing attention is assigned to obesity specifically due to its epidemiologic studies yielding inconsistent results (Table 1). Nevertheless the majority of studies have reported a significant association between obesity and high BMI with DR [30-38]. Conversely others have reported an association between low BMI and DR [39-41]. This lack of consensus may be partly explained by methodological differences, differences in study participants, lack of comprehensive anthropometric measurements, inadequate clinical sample size and particularly racial or ethnic differences [39,40].

| Year/ Authors | Study | Country/ Population | Number of patients/ participants | DM type | Relationship between DR and obesity |
|---------------|-------|---------------------|----------------------------------|---------|-----------------------------------|
| 1984 Klein et al. [38] | The Winsconsin epidemiologic study of DR | Southern Winconsin | 1370 | Type 2 according to age of 30 years or more at time of diagnosis | Negative |
| 1997 Klein et al. | The Winsconsin epidemiologic study of DR | Southern Winconsin | 1370 | Type 2 according to age of 30 years or more at time of diagnosis | Negative |
| 1998 Dowse et al. [40] | Multiethnic population of Mauritius | 911 of 6553 participants | 6553 | Type 2 and impaired glucose tolerance | Negative |
| 2001 Zhang et al. [29] | Diabetes Control and Complications Trial (DCCT) | Belgium | 1441 | Type 1 | Positive |
| 2005 Chaturvedi et al. [52] | The EURODIAB Prospective Complications study | Europe | 764 | Type 1 | Positive |
| 2003 Van Leiden et al. [32] | The Hoorn Study | Netherlands | 626 of 3553 participants | Type 2 | Positive |
| 2003 Henricsson et al. [30] | Diabetes Incidence Study in Sweden (DISS) | Sweden | 806 | Type 1 and type 2 | Positive |
| 2005 De Block et al. [36] | | Belgium | 592 | Type 1 | Positive |
| 2010 Raman et al. [39] | SankaraNethralaya DR Epidemiology and Molecular Genetic Study (SN-DREAMS-I) | Urban Indian population | 1414 | Type 2 | Negative |
Diabetic Retinopathy and Obesity - Proposed Pathophysiological Mechanisms

Although the underlying pathophysiological mechanisms supporting the relationship between obesity and DR are yet to be defined several biological theories have been suggested comprising the potential involvement of platelet function, blood viscosity, aldose reductase activity and vasoproliferative parameters such as Vascular Endothelial Growth Factor (VEGF). Further both metabolic syndrome and increased oxidative stress due to their association with obesity and DR have also been suggested as possible pathophysiological mechanisms [15,35,42-44].

Many investigations have been directed to the role of angiogenic factors particularly the VEGF in the pathogenesis of DR whereby the concentration of VEGF a potent growth factor which promotes angiogenesis has been found to be higher in the vitreous of eyes with PDR [45]. Patients with proliferative retinopathy also demonstrate elevated peripheral markers of angiogenesis and endothelial dysfunction, suggesting a participating role for these processes in the pathogenesis of PDR [46]. Adipose tissue produces several vascular growth factors which stimulate angiogenesis and are known to be associated with the expansion of the capillary bed in regional adipose areas [43]. In the serum of obese individuals elevated angiogenic factors including VEGF have been observed partially owing to the presence of oxidative stress [11] providing additional confirmation of the possible link between obesity and PDR [11,43-46]. Further a positive correlation between BMI and serum concentration of VEGF, angiopoietin-2 and angiogenin was also found [43].

Recent evidence suggests that the biochemical link between diabetes and development of its complications in both types of diabetes includes the two interactive mechanisms namely increased inflammation and oxidative stress. In diabetes a chronic state of low-intense body inflammation episodically aggravated by hyperglycemic fluctuations which appear to be related to elevated indicators of inflammation, immune activation and oxidative stress is present [47]. Likewise obesity is also associated with the state of elevated inflammation, oxidative stress and insulin resistance with growing evidence connecting their mutual interrelationship [48]. Obesity increases the prevalence of several risk factors which have previously demonstrated to be involved in DR onset and development particularly including inflammatory markers. New data suggests that obesity is associated with both increased local adipose and more generalized systemic inflammation [47-49].

Adipose tissue is regarded to be an active endocrine and paracrine pro-inflammatory organ which releases a large number of cytokines and bioactive mediators such as interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) leptin, adiponectin, that influence not only body weight homeostasis but also lipid levels, coagulation, atherosclerosis and diabetes occurrence, inflammation, oxidative stress, insulin resistance and DR development. Moreover endothelial dysfunction (ED) as an early indicator of DR is also present in obesity and is characterized by increased levels of intracellular adhesion molecule-1 (ICAM-1) [49-52]. ED caused by oxidative stress and inflammation processes both connected to diabetes and obesity plays a key role in the pathogenesis of diabetic angiopathy and arterial wall damage. It is well established that endothelial dysfunction is involved in diabetic retinopathy as well as nephropathy and microalbuminuria is considered to be a marker of ED [51]. Oxidative stress has been proposed to be a potential pathogenetic mechanism linking obesity and insulin resistance with ED [48]. It is considered to be the common factor underlying insulin resistance and may explain the presence of inflammation since the release of IL-6, mainly from abdominal tissue may have a key role in the relationship between oxidative stress and ED. IL-6 contributes to C-reactive protein (CRP) elevation and low-grade inflammatory state and also has an obvious relationship with coagulation, insulin resistance, dyslipidemia and ED [48]. Hyperglycemia via glucose auto oxidation and/or non-enzymatic glycation with concurrent impairment of the antioxidant defence system leads to an increased production of reactive oxygen species (ROS). Previous reports have demonstrated that ROS, the signalling molecules of endothelial cell damage contribute to the modulation of endothelial function as well as the over expression of inflammatory cytokines [50]. Schram et al. investigated the association of inflammatory markers with vascular complications in type 1 diabetes and has shown a strong and independent association of CRP, IL-6 and TNF-α with DR [53]. The profile of intraocular TNF-α and IL-6 in diabetic subjects with different degrees of DR show that intraocular inflammation seems to be involved in PDR however is not prominent in the early stages of retinopathy development. Diabetic subjects exhibit overall increased inflammatory activity compared to non-diabetics, as demonstrated by increased serum levels of TNF-α [54]. A study conducted to determine a possible association between serum levels of inflammatory markers and PDR show the association between

| Year | Authors | Study | Country | Participants | Type | Results |
|------|---------|-------|---------|--------------|------|---------|
| 2010 | Lim et al. | Singapore Malay Eye Study (SiMES) | Urban Malay adults | 718 participants | Type 2 | Negative |
| 2011 | Dirani et al. | Diabetes Management Project (DMP) | Victoria/Australia | 492 | Type 1 and type 2 | Positive |
| 2013 | Li et al. |  | Beijing/China | 2194 | Type 2 | Positive |
| 2013 | Kaštelan et al. |  | Croatia | 545 | Type 2 | Positive |

Table 1: Studies investigating the relationship between diabetic retinopathy and obesity.

DM: Diabetes Mellitus; DR: Diabetic Retinopathy
TNF-α and PDR in type 1 diabetic patients indicating that inflammation may play a significant role in the pathogenesis of PDR [55]. Some results suggest that nitric oxide (NO), soluble IL-2 receptor (sIL-2R), IL-8 and TNF-α may play important roles in the pathophysiology and progression of DR and via activity on the endothelial cells may jointly effect the course and progression of DR [56]. A study conducted to investigate the involvement of the inflammatory processes in the pathogenesis of PDR demonstrate an increase in soluble ICAM-1 (sICAM-1) and soluble vascular adhesion molecule-1 (sVCAM-1) levels, as well as their correlation with high vitreous IL-6 and TNF-α concentrations in patients with PDR which in turn confirm their inflammatory nature [57].

Pathways of inflammation and ED are considered to be important in the pathogenesis of DR [58]. In a clinical study with type 2 diabetic patients the level of adhesion molecules were higher in subjects with as opposed to those without retinopathy [59]. Likewise in another study inflammatory and endothelial function markers were strongly associated with the presence of DR [60]. Similarly E-selectin values were found to be increased in patients with type 1 diabetes mellitus and retinopathy [61] however not observed in subjects with type 2 and retinopathy [62]. Tomić et al. demonstrated that the association between obesity, inflammation and other risk factors plays an important role in the endothelial impairment involved in the pathogenesis of DR [41,63]. However, only a few studies have examined the role of systemic inflammation in DR development [53]. In two case-control studies diabetic subjects with macular oedema (ME) or PDR had higher levels of vascular endothelial growth factors and cytokines in their vitreous then those without ME or PDR [64,65].

Oxidative stress has been proposed to be a potential pathogenetic mechanism linking obesity and insulin resistance with ED. It may explain the presence of inflammation since the release of IL-6, mainly from abdominal tissue may have an essential role in the relationship between oxidative stress and ED. IL-6 contributes to CRP elevation and a low-grade inflammatory state and is also closely linked to coagulation, insulin resistance, dyslipidemia and ED [48]. Ultimately obesity and DR may also be connected owing to increased oxidative stress as a result of its association with hyperleptinemia [48,52]. Plasma leptin levels are seen to be elevated in obesity and correlate positively with both visceral and subcutaneous fat areas [52]. High plasma leptin levels have been found to be related to both hypertensive and diabetic retinopathy [52]. Pertinent to DR recent findings show that leptin promotes vascular endothelial cell proliferation and angiogenesis in vitro and neovascularization in vivo [52,66]. Known data demonstrate leptin involvement in retinal diseases with elevated leptin levels in the human vitreous in PDR and retinal detachment as well as its presence in fibrovascular epiretinal tissue [67,68]. Uckay et al. show a positive correlation of advanced forms the DR with the increase of the plasma leptin levels. Previously observed leptin-induced promotion of angiogenesis and neovascularization supports the possibility that it may have a role in the advancement of DR to its proliferative phase [51]. Leptin levels in vitreous humour may be a possible factor in the course of vascular and proliferative retinal diseases [69]. It is considered that the intraocular production of leptin is not critically involved in the etiopathogenesis of PDR, however recent results indicate that serum diffusion is a relevant source of leptin in vitreous fluid [70].

Alternatively, adiponectin levels correlate negatively with visceral and subcutaneous fat areas whilst its low levels are associated with obesity and insulin resistance [42,50,71]. An increased level of adiponectin was found in diabetic and nondiabetic subjects with impaired kidney function as well as in type 1 diabetic patients without complications and particularly in those with diabetic nephropathy [63,66,72,73]. Adiponectin inhibits monocyte attachment to the vascular bed by decreasing the expression of adhesion molecules (VCAM-1, ICAM-1, E-selectin) in endothelial cells and also suppresses the production of proinflammatory cytokine TNF-α by macrophages [74,75]. Further adiponectin protects against the development of inflammation and provides an additional link between obesity and vascular inflammatory processes [75]. Clinically lean patients with type 2 diabetes having DR (proliferative as well as non-proliferative) are reported to have lower levels of adiponectin than patients without retinopathy [76]. Adiponectin is likely to be on of the main contributors to the pathogenesis of both type 2 diabetes and DR. Conversely, type 1 diabetic patients with microvascular complications have higher serum adiponectin levels than those without complications [77]. The elevated adiponectin concentrations observed in subjects with microvascular disease may indicate altered regulation of this adipocytokine in patients with complications associated with type 1 diabetes [78]. The clinical significance of adipocytokines in terms of a causative role in metabolic disorder and microangiopathy in diabetes should certainly be investigated in the future.

Epidemiological data from various studies have identified hyperlipidemia and hypertension which are connected with obesity as risk factors for DR [30,43,66]. In fact, metabolic syndrome encompassing these conditions has also been shown to be associated with retinopathy [79]. Moreover, many overweight type 1 diabetic patients are difficult to treat and require a relatively high dose of insulin to achieve adequate glycemic control [35,63]. Thus it is possible that metabolic syndrome and its associated insulin resistance although usually associated with type 2 diabetes may also be a clinical feature for some patients with type 1 [10,79]. It is generally established that in obese and diabetic individuals inflammatory and oxidative processes are found to be consistently elevated with complex underlying activating mechanisms. Further, the level of inflammatory activation seems to be proportional to severity of obesity in overweight individuals and the quality of glycemic control in type 1 diabetic patients respectively. A better and more detailed understanding of all the facets linking obesity and diabetes with the components of the underlying inflammatory and oxidative dysregulation represents the basis for future ability of successful prevention and management of DR [11,80].

Concise obesity may increase the risk of DR development via several established mechanisms such as hypertension, dyslipidemia and glucose dysmetabolism as well as some new mechanisms which still need to be elucidated such as IL-6, TNF-α, leptin, adiponectin, and adhesion molecules. Mutually they may lead to an increase in oxidative stress, insulin resistance, endothelial dysfunction and consequently DR development [50,80] (Table 2). Furthermore, physical activity and weight loss as lifestyle factors provide some additional evidence to support the relationship between obesity and DR whereby weight loss has been seen to delay the onset of diabetic complications including DR [81]. Taking this into account the application of interventions that promote weight reduction may therefore also reduce the risk of DR. Lifestyle changes with personal responsibility specifically towards weight loss has been advocated as a key factor in the prevention of diabetes and delaying diabetic complications including retinopathy in susceptible patients [42,81].
Table 2: Obesity in the pathogenesis of diabetic retinopathy.

Conclusion

In conclusion, DR is a complex disease with many proven and some insufficiently verified risk factors including obesity. It has been shown that obesity in correlation with poor glycaemic control, hypertension and dyslipidaemia appears to be associated with the progression of DR and may be a relevant factor involved in DR occurrence and development. Several findings demonstrate the value of obesity assessment as a possible modifiable risk factor with potential clinical implications in the management of DR. Since weight gain is changeable and may be managed by lifestyle intervention additional studies are required to investigate and fully clarify the pathogenic role of obesity and weight loss in retinal diabetic complications. Thus study findings which confirm the association of obesity with the presence and severity of DR undeniably open up the necessity for further research and intervention.

References

1. Friedman N, Fanning EL (2004) Overweight and obesity: an overview of prevalence, clinical impact, and economic impact. Dis Manag 7 Suppl 1: S1-6.
2. Friedrich MJ (2002) Epidemic of obesity expands its spread to developing countries. JAMA 287: 1382-1386.
3. Hill JO, Catenacci V, Wyatt HR (2005) Obesity: overview of an epidemic. Psychiatr Clin North Am 28: 1–23.
4. Formiguera X, Cantón A (2004) Obesity: epidemiology and clinical aspects. Best Pract Res Clin Gastroenterol 18: 1125-1146.
5. Melendez-Ramirez LY, Richards RJ, Cefalu WT (2010) Complications of type 1 diabetes. EndocrinoMetab Clin North Am 39: 625-640.
6. American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32 Suppl 1: S62-67.
7. Forlenza GP, Rewers M (2011) The epidemic of type 1 diabetes: what is it telling us? Curr Opin Endocrinol Diabetes Obes 18: 248-251.
8. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Care 33 Suppl 1: S1-6.
9. Haslam DW, James WP (2005) Obesity. Lancet 366: 1197-1209.
10. Libman JM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ (2003) Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26: 2871-2875.
11. Tran B, Oliver S, Rosa J, Galassetti P (2012) Aspects of inflammation and oxidative stress in pediatric obesity and type 1 diabetes: an overview of ten years of studies. Exp Diabetes Res 2012: 683680.
12. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B (2010) The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 17 Suppl 1: S3-8.
13. Moss SE, Klein R, Klein BE (1998) The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105: 998-1003.
14. Aiello LM (2003) Perspectives on diabetic retinopathy. Am J Ophthalmol 136: 122-135.
15. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, et al. (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35: 556-564.
16. Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, et al. (2003) The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 26: 1731-1737.
17. Harris MI, Klein R, Wellborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15: 815-819.
18. Turner R, Cull C, Holman R (1996) United Kingdom Prospective Diabetes Study 17: a 15-year follow-up of randomized controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124: 136-145.
19. Diabetes Control and Complication Trial / Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389.
20. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, et al. (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44: 156-163.
21. Kastelein S, Tomić M, Pavan J, Orešković S (2010) Maternal immune system adaptation to pregnancy--a potential influence on the course of diabetic retinopathy. Reprod Biol Endocrinol 8: 124.
22. Kastelein S, Tomić M, Salopek-Rabatić J, Pavan J, Lukenda A, et al. (2013) The association between the HLA system and retinopathy development in patients with type 1 diabetes mellitus. Coll Antropol 37 Suppl 1: 65-70.
23. Davis MD (1992) Diabetic retinopathy. A clinical overview. Diabetes Care 15: 1844-1874.
24. [No authors listed] (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986.
25. Sjölie AK, Stephenson J, Aldington S, Kohner E, Janka H, et al. (1997) Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 104: 252-260.
26. Karamanos N, Porta M, Songini M, Meteklo Z, Kerenyi Z, et al. (2000) Different risk factors of microangiopathy in patients with type 1 diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia 43: 348-355.
27. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr (1999) Bodymass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341: 1097-1105.
28. Haupt E, Benecke A, Haupt A, Herrmann R, Vogel H, et al. (1999) The KID Study VI: diabetic complications and associated diseases in younger type 2 diabetes still performing a profession. Prevalence and correlation with duration of diabetic state, BMI and C-peptide. Exp Clin Endocrinol Diabetes 107: 435-441.
29. Zhang L, Krzontowski G, Albert A, Lefebvre PJ (2001) Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24: 1275-1279.
30. Henriksson M, Nyström L, Blomhö G, Osteen J, Kullberg C, et al. (2003) The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26: 349-354.
31. [No authors listed] (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes.
patients without clinical macrovascular complications. Diabetes Res Clin Pract 79: 337-342.

51. Uckaya G, Ozata M, Bayraktar Z, Erten V, Bingol N, et al. (2000) Is leptin associated with diabetic retinopathy? Diabetes Care 23: 371-376.

52. Siira-Honigmann MR, Nath AK, Murakami C, Garcia-Cardeña G, Papapetropoulos A, et al. (1998) Biological action of leptin as an angiogenic factor. Science 281: 1683-1686.

53. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD, et al. (2005) Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia 48: 370-378.

54. Gustavsson C, Agardh CD, Agardh E (2013) Profile of intracellular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol 91: 445-452.

55. Gustavsson C, Agardh E, Bengtsson B, Agardh CD (2008) TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications 22: 309-316.

56. Doganay S, Evereklioglu C, Er H, Türköz Y, Sevinç A, et al. (2002) Comparison of serum NO, TNF-alpha, IL-1beta, sII-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 16: 163-170.

57. Adamiec-Mroczek J, Oficjalska-Mlynczak J (2008) Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes—role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246: 1665-1670.

58. Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Prog Retin Eye Res 30: 343-358.

59. Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, et al. (2002) Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 19: 822-826.

60. van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, et al. (2001) Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 44: 1300-1306.

61. Spijkerman AM, Gall MA, Tarnow I, Tweek JW, Lauritzen E, et al. (2007) Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabet Med 24: 969-976.

62. Ersanli D, Top C, Oncül O, Aydin A, Terekeci H (2007) Relationship between serum soluble E-selectin levels and development of diabetic retinopathy in patients with type 2 diabetes. Scand J Clin Lab Invest 67: 474-479.

63. Tomic M, Ljubicic S, Kastelan S (2013) The role of inflammation and endothelial dysfunction in the pathogenesis of diabetic retinopathy. Coll Antropol 37: 51-57.

64. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, et al. (2001) Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 15: 257-259.

65. Funatsu H, Yamashita H, Ikeda T, Mimura T, Shimizu E, et al. (2003) Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol 135: 321-327.

66. Matsuda M, Kawasaki F, Yamada K, Kanda Y, Saito M, et al. (2004) Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. Diabet Med 21: 881-888.

67. Gariano RF, Nath AK, D’Amico DJ, Lee T, Sierra-Honigmann MR (2000) Elevation of vitreous leptin in diabetic retinopathy and retinal detachment. Invest Ophthalmol Vis Sci 41: 3576-3581.

68. Maberley D, Cui JZ, Matsubara JA (2006) Vitreous leptin levels in retinal disease. Eye (Lond) 20: 801-804.

69. Er H, Do˘Ayan S, Ozerel E, YA¸rekli M (2005) Adrenomedullin and leptin levels in diabetic retinopathy and retinal diseases. Ophthalmologica 219: 107-111.
70. Hernández C, Lecube A, Castellanos JM, Segura RM, Garat M, et al. (2004) Intravitreous leptin concentrations in patients with proliferative diabetic retinopathy. Retina 24: 30-35.

71. Wong TY, Duncan BB, Golden SH, Klein R, Couper DJ, et al. (2004) Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. Invest Ophthalmol Vis Sci 45: 2949-2954.

72. Doumatey AP, Zhou J, Huang H, Adeleye J, Balogun W, et al. (2012) Circulating adiponectin is associated with renal function independent of age and serum lipids in west africans. Int J Nephrol 2012: 730920.

73. Habeeb NM, Youssef OI, Saab AA, El Hadidi ES (2012) Adiponectin as a marker of complications in type 1 diabetes. Indian Pediatr 49: 277-280.

74. Wang B, Trayhurn P (2006) Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 452: 418-427.

75. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14: 561-566.

76. Yilmaz MI, Sonmez A, Acikel C, Celik T, Bingol N, et al. (2004) Adiponectin may play a part in the pathogenesis of diabetic retinopathy. Eur J Endocrinol 151: 135-140.

77. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A (2005) Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48: 1911-1918.

78. Hadjadj S, Aubert R, Fumeron F, Pean F, Tichet J, et al. (2005) Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia 48: 1088-1092.

79. McGill M, Molynieux L, Twigg SM, Yue DK (2008) The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications 22: 18-23.

80. Khavandi K, Amer H, Ibrahim B, Brownrigg J (2013) Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis 4: 242-261.

81. Sheard NF (2003) Moderate changes in weight and physical activity can prevent or delay the development of type 2 diabetes mellitus in susceptible individuals. Nutr Rev 61: 76-79.